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The M protein ofgroup A streptococci is a fibrous dimer ofa helices arranged
in a coiled coil extending ^"50 nm from the surface of these organisms (1, 2) .
Due to its profound antiphagocytic effect, this molecule serves as the primary
virulence factor for these streptococci (3) which are cleared from the infected
host only after type-specific opsonic antibodies are produced to the M protein
(4). mAbs to the native M6 protein and DNA hybridization studies on the M6
gene indicate that the N112-terminal region of this molecule is variable among
M serotypes, whereas the carboxy-terminal half is conserved (5-8) . This suggests
that type specificity may reside in the NH2-terminal half of the M protein, which
is distal to the cell surface (9) . While a number of studies on a variety of M
protein fragments derived from the NH2-terminal half of the molecule suggest
the importance of this region in the production of opsonic antibodies (10-14),
no systematic approach concerning the binding site and function of specific
antibodies to the completeM molecule has yet been reported .
To help delineate the location ofopsonogenic determinants on the M6 protein,
mAbs raised against the native M6 molecule were examined for their ability to
opsonize type 6 streptococci . Four ofthesemonoclonals thathad defined epitopes
(reference 6 ; Jones, K . F ., S . K . Hollingshead, J . R . Scott, and V . A . Fischetti,
manuscript in preparation) were examined for their IgG subclasses and ability to
fix human complement . In addition, antisera against synthetic peptides repre-
senting various areas of the native M6 protein were examined for their opsonic
capabilities . These studies revealed that opsonization of streptococci is a function
of the location of the antibody-binding site on the M molecule .
Materials and Methods
Purified M6 Proteins. M6 protein extracted from streptococcal cells by group C
streptococcal phage-associated lysin (LysM6) was purified as described (15). M6 protein
(ColiM6) was extracted and purified from an Escherichia coli strain expressing the structural
gene for M6 protein (9) .
Production ofmAbs.
￿
mAbs against eitherLysM6 or ColiM6 were produced and protein
A purified from culture supernatants as described (5, 6) .
Bacterial Strains.
￿
Group A streptococcal clinical isolates representing 56 M serotypes
were from The Rockefeller University culture collection and were listed previously (6) .
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SynthesisofPeptides.
￿
Peptides were synthesized by the method of Barany and Merrifield
(16) and were based on the sequence of the native M6 protein gene (17). A cysteine
residue was placed at the COON terminus for linkage to a carrier molecule. Synthesized
peptides were purified by reverse-phase HPLC on a Brownlee C8 column (BrownleeLabs,
Santa Clara, CA) using an acetonitrile-0.05% trifluoroacetic acid buffer gradient. The
composition of purified peptides was verified by quantitative amino acid analysis (below).
The position on the M6 molecule and the amino acid sequences for synthesized peptides
are listed in Table III and illustrated in Fig. 1.
Analytical Methods.
￿
For amino acid analysis, peptides hydrolyzed in 6 N HCl or 6 N
HCl/0.1 % phenol at a Picotag Work Station (Waters Associates, Milford, MA) were
derivatized with ethanol, triethylamine, water, and phenylisothiocyanate (7:1 :1 :1) and
analyzed with amodel 840 Data Module usinga NovapakC18 column (WatersAssociates).
Amino acid sequence analysis was performed by automated Edman degradation in a gas
phase sequencer (model 470A; Applied Biosystems, Inc., Foster City, CA). The PTH
amino acids were identified by HPLC on a C18 column using either a 1084B analyzer
(Hewlett-Packard Co., Rockville, MD) or a PTH analyzer (model 120A; Applied Biosys-
tems, Inc.). All analytical procedures were performed by The Rockefeller University
Central Biotechnology Facility.
Coupling of Synthetic Peptide to Carrier Protein.
￿
Peptides were coupled to the carrier
proteinOVAthroughtheCOOH-terminal cysteine of thepeptide. Theheterobifunctional
reagent 3-(2-pyridyldithio)-propionic acid N-hydroxysuccinimide ester (Pharmacia Fine
Chemicals, Piscataway, NJ) was used for thiolation of OVA (Worthington Biochemi-
cals/CooperBiomedical, Inc., Malvern, PA) according to the manufacturers instructions.
In general, 5.0 mg of purified peptide in 100 ul 0.01 M PBS, pH 7.5, was coupled to 8.0
mg of functionalized OVA in 1.7 ml PBS. All solutions were degassed with nitrogen. The
mixture was allowed to mix at room temperature for 2 hand then overnight at 4°C. The
solution was dialyzed against distilled water and stored frozen in aliquots at -70°C.
Rabbit Immunization.
￿
New Zealand white rabbits were bled and immunized intrader-
mally with 200-400 ug of peptide-coupled OVA emulsified in CFA at multiple sites.
Animals were boosted intramuscularly 30, 71, and 98 d afterthe first immunization with
100-200 ,ug of the respective peptide in IFA. All rabbits were bled 3 wk after the first
immunization and 7-10 d after each booster immunization. All sera were filter sterilized
and stored at 4°C.
Affinity Purification ofSynthetic Peptide-specific Antibodies.
￿
To isolate synthetic peptide-
specific antibodies from the polyclonal rabbit sera, synthetic peptides were linked to a
solid matrix either by free aminogroups or by the terminal cysteine. Peptides were linked
by free amino groups to a glutardialdehyde-activated affinity adsorbent (Boehringer
Mannheim Biochemicals, Indianapolis, IN) following the manufacturers instructions.
Briefly, 3-5 mg of peptide was dissolved in 2.5 ml of 0.9% NaCl, added to 0.5 g of the
affinity adsorbent, and rotated 4 h at room temperature in a 1-cm-diam column. The
peptide-coupled matrix was then washed sequentially with 1.5% NaCl, 0.3 Methanolamine
(pH 7.0), 0.9% NaCl, 0.5 M propionicacid, 0.9% NaCl, and 0.01 M PBS (pH 7.4).
Coupling of synthetic peptides to thiopropyl-Sepharose 6B (Pharmacia Fine Chemicals)
viacysteine wasperformedby amodification of the method of Carlsson et al. (18). Briefly,
3 mg of peptide was suspended in 1 ml of 0.14 M 2-ME and 1 mM disodium EDTA in
0.2 M ammonium bicarbonate, pH 8.5, in a tube flushed with nitrogen. This suspension
was then rotated for 4 h at room temperature and the 2-ME was subsequently removed
by six successive lyophilizations. The peptide was then dissolved in degassed 0.1 M Tris,
pH 7.5, containing 6 M guanidine-HCI, 0.5 M NaCl, and 1 mM EDTA. The peptide
solution was then added to 0.5 g of thiopropyl-Sepharose 6B (in a 1-cm-diam column)
that had been washed successively with the Tris/NaCI/EDTA buffer (without guanidine)
and then with the same buffer with guanidine. The column was sealed under nitrogen
and rotated overnight at room temperature. Unbound peptide was eluted with the
Tris/NaCI/EDTA buffer (without guanidine) and the column was reequilibrated with the
same buffer.
Anti-synthetic peptide rabbit serum (3 ml) was adsorbed to the appropriate peptide-1116 ANTIBODY BINDING LOCATION IN STREPTOCOCCAL PHAGOCYTOSIS
linked glutardialdehyde or thiopropyl-Sepharose affinity column by rotating the mixture
for 4 h at 37°C. After washing the resin extensively with PBS, adsorbed antibodies were
eluted with 0.1 M glycine, pH 2 .5, neutralized immediately, dialyzed against PBS, and
concentrated to their original volume in a Centricon-30 (Amicon Corp., Danvers, MA).
Bacterial Dot Blot Immunoassay.
￿
Cross-reactivity of mAbs with various group A strep-
tococcal M serotypes was investigated with the bacterial dot blot immunoassay as described
(6). mAbs were adjusted to a concentration of 10 Wg/ml. Affinity-purified anti-peptide
antibodies were adjusted to a dilution that would give an ELISA reading of 1 .0 at 405
nm after 60 min at 37 - C.
Bactericidal Assay.
￿
Purified mAbs and anti-peptide sera were assayed for their ability
to opsonize group A, M type 6 strain D471 streptococcal cells by the indirect bactericidal
assay as described (4).
ELISA. The ELISA was performed as described (19). Titers are expressed as the
dilution giving a reading of >_ 1 .0 at 405 nm after a 30-min incubation at 37'C. mAbs
were diluted from a 1 mg/ml stock.
Complement Fixation Assay.
￿
This assay was a modification of the method as outlined by
Hudson and Hay (20). All dilutions were made in 0.03 M veronal buffered saline
containing 2.5 mM MgC12, 0.75 mM CaC12, and 0.1% gelatin. The reaction mixture
consisted of 50 ,l of antigen (dilutions of ColiM6 or of an OD65o = 1 .0 suspension of M6
cells), 50 Al of mAb, and 50 tsl of human complement in V-bottomed microtiter plates
(Nunc Products, Roskilde, Denmark). Plates were incubated overnight at 4°C and then
30 kl of SRBC coated with anti-SRBC antibodies were added, shaken, incubated at 37°C
for 30 min, shaken, and incubated an additional 10 min. Plates were then placed in an
ice bath for 5 min, centrifuged at 500 g for 10 min, and 100 i1 of the supernatant was
transferred to a flat-bottomed plate (Immulon II; Dynatech Laboratories, Inc., Chantilly,
VA) and read in an ELISA reader (Physica, Inc., New York, NY) at 405 nm to determine
the amount of cell lysis.
mAb Isotypes.
￿
The method for isotyping followed the ELISA technique described (19)
with reagents added in the following order: plates were coated with anti-mouse isotype-
specific sera (Miles Laboratories, Inc., Naperville, IL) at a 1 :1,000 dilution, followed by
incubation with the mAb to be screened, then anti-mouse IgG alkaline phosphatase
conjugate, and finally the p-nitrophenyl phosphate substrate.
Results
Opsonization of M6 Streptococci by mAbs.
￿
The bactericidal assay was used to
identify those mAbs prepared against the native M6 protein (derived from two
different hybridoma fusions) that allow for the phagocytosis of M6 streptococci.
Of 19 mAbs screened, only one (mAb 3B8) was capable ofcompletely opsonizing
the M6 organisms (Table I). While some of the other mAbs, particularly 9F10,
showed some opsonic activity, they only did so with 1 mg per assay, while 3B8
required only 250,ug to completely opsonize these cells. The epitopes for three
of the nonopsonic mAbs were localized previously; the epitopes for mAb IOAI I
were located within the "B" repeat region of the M6 protein at residues 134-
139, 159-164, and 184-189, and the epitopes for mAbs IOB6 and 1OF5 were
both within residues 275-289 near the center of this fibrillar molecule (Fig. 1 ;
reference 6). The epitopes for opsonic mAb 3B8 were at residues 41-46, 55-
60, and 69-74 within the "A" repeat region (Fig. 1 ; Jones, K. F., S. K. Hollings-
head, J. R. Scott, and V. A. Fischetti, manuscript in preparation).
Cross-reactions of mAbs with other M Serotypes.
￿
mAbs 10A11, IOB6, and IOF5
were previously shown to cross-react with 10, 30, and 30 different group A M
serotypes, respectively, in bacterial dot blot immunoassays, indicating that despite
their location on the M6 molecule, the immunodeterminants for these mAbsJONES AND FISCHETTI
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TABLE I
Bactericidal Assay ofAnti-M6 mAbs vs . M Type 6Streptococcal Strain D471
Bactericidal assay was performed according to the method of Lancefield as follows: 0.1 ml of log
phase bacteria was inoculated into tubes containing 1 mg of appropriate antibody in 0.1-0.2 ml
PBS and 0.4 ml of heparinized normal human blood ; after 3 h of incubation at 37°C, bacterial
growth or phagocytosis in stationary or rotated tubeswas assayed by plating 0.1 ml of each culture
in 0.8% sheep blood agar. Counts are expressed as CFU .
* Contained0.25 mg of antibody .
NH2 ￿50
￿
100
￿
150
￿
200
￿
250
￿
300
￿
350
￿
400
￿
COON
￿
FIGURE 1 .
￿
Position of mAb ep-
I
￿
I
￿
I
￿
I
￿
I
￿
I
￿
I
￿
I
￿
I
￿
I
￿
itopes and synthetic peptides on
EA$A*A* .A*Aj
￿
the amino acid sequence of the o
￿
M6 protein (17) . Shaded areas
WALL --1-Wi
￿
with A, B, C, and D represent
---S-M6c1-211
￿
amino acid sequence repeats
»»»MAb3e8
￿
within the M6 molecule, as de-
~-+ S-M6 (95-108)
￿
scribed (2) . Those mAbs with
S-M6(121-145)
￿
more than one epitope position
»MAb10A11
￿
on this chart (mAbs 3118 and
"--S-M6(216-235)
￿
1OA11) and the synthetic peptide
--~MAbs1OB6 and 10175
￿
with
￿
repeated
￿
sequences
￿
(S-
---S-M6(3o8-327)
￿
M6[121-145]) are represented by
multiple sets ofdots and lines (see
Tables 11 and III for actual amino acid residue positions) . WALL is the COOH-terminal region of
the molecule buried within the cell wall andMA is themembrane anchor region at residues 417-441
(Pancholi, V., and V. A. Fischetti, manuscript submitted for publication) .
were accessible on the whole organism (6) . Of the 56 M serotypes tested by the
dot blot method, opsonic mAb 3118 demonstrated type specificity by reacting
only with the homologous M6 strain (data not shown) .
ELISA Titers ofAnti-M6 mAbs .
￿
mAbs were assayed for their binding titers to
the ColiM6 protein by ELISA. All four mAbs demonstrated high titers to the
native M6 molecule with 10116 showing an exceptionally high binding capacity
relative to the others (Table II) .
IgG Subclass and Complement Fixation by Anti-M6 mAbs .
￿
Even though all four
mAbs were capable of binding to whole streptococcal cells, only one (3B8) had
the ability to initiate phagocytosis (Table I) . To help explain the reason for this
observation, mAbs were further characterized with respect to their IgG subclass
and capacity to consume human complement in the presence of ColiM6 or M6
streptococcal cells (Table II). Despite their inability to opsonize type 6 strepto-
cocci, mAbs lOB6 (IgG2a) and lOF5 (IgG2b) were able to effectively fix comple-
ment, although mAb 10175 was slightly less effective when bound to ColiM6 .
Antibody Inocu-
lated Stationary Rotated Antibody Inocu-
lated Stationary Rotated
10116 48 >2,500 >2,500 10A11 48 >2,500 >2,500
3118 30 >2,500 0* 1OF5 30 >2,500 >2,500
141111 30 >2,500 >2,500 14G12 30 >2,500 >2,500
15134 30 >2,500 >2,500 91710 24 >2,500 533
10HI 24 1,940 1,162 12G4 24 >2,500 1,858
141110 24 >2,500 1,784 15E1 24 >2,500 1,236
2H4 24 >2,500 >2,500 4G8 24 >2,500 >2,500
5G10 24 >2,500 >2,500 11E1 24 >2,500 >2,500
12115 24 >2,500 >2,500 13174 24 >2,500 >2,500
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TABLE II
EpitopePosition, IgG Subclass, ELISA Binding Titer, Complement Fixation, and Opsonic
Activity ofAnti-M6 mAbs
* ELISA binding titers are expressed as the reciprocal of the dilution that gives an absorbance of
1.0 at 405 nm after 30 minof incubation at 37°C. All mAbs were adjusted to a concentration of
1 mg/ml before dilution.
t Humancomplement fixation by mAbs reacted with either ColiM6 or M6 streptococcal strain D471
cells. Values areexpressedas theamount ofmAb(, g/ml) needed for 50% lysis ofindicatorSRBCs
when complexed with optimal concentrations of ColiM6 (usually 50 fag/ml) or M6 cells (usually a
1:8 or 1:16 dilution of the original stock suspension) relative to complement controls.
5 See Table I.
No complement fixedat 400 gg/ml.
mAb lOA11, an IgG1, did not fix complement, even at the relatively high
antibody concentrations used. mAb 3118 (IgG3) was capable of fixing human
complement when bound to either ColiM6 or M6 cells. Very little variation was
observed in the degree to which 10116, lOF5, or 3B8 wereable to fix complement,
despite the fact that IOB6 and 1OF5 are of the subclasses regarded to be the
most efficient at complement fixation (21).
Analysis of Anti-synthetic Peptide Antibodies.
￿
To investigate areas of the M
molecule not included by the epitopes ofthe mAbs, peptides representing various
regions of the M6 protein (Fig. 1) were synthesized. Sera obtained from rabbits
immunized with OVA-coupled synthetic peptides were assayed for their ability
to bind to the M6 protein (ELISA) and opsonize type 6 cells in bactericidal assays.
The data compiled in Table III shows that all peptides produced antibodies with
high binding titers to the purified M6 protein, although antisera to S-M6(95-
108) and S-M6(121-145) were somewhat less reactive. The bactericidal data
demonstrates that only the amino-terminal peptide S-M6(1-21) was capable of
eliciting antibodies opsonic for the type 6 streptococci. Although antibodies to
S-M6(95-108) showed marginal activity in bactericidal assays, they were not
nearly as efficientas those prepared againstthe amino terminus. Affinity-purified
antibodies were analyzed by bacterial dot blot immunoassay to determine their
reactivity to intact streptococcal cells. All antibodies, except those prepared
against S-M6(308-327) were able to bind the streptococcal-bound M6 protein.
Discussion
The current study shows three mAbs, each able to fix complement and bind
to M protein on the cell surface (6) and, therefore, potentially capable of
opsonizing M6streptococci, yetonly one (mAb 3118) did so. The major difference
Antibody
M6 protein
epitope
position
IgG subclass ELISA titer*
C'
ColiM6
fixation*
M6 cells
Opsonicc
activity
3118 41-46 IgG3 2,500 25-50 25-50 +
55-60
69-74
IOAll 134-139 IgG1 3,200 -1 -I -
159-164
184-189
10116 275-289 IgG2a 179,800 12 .5-25 25-50 -
IOF5 275-289 IgG2b 11,700 50-100 25-50 -JONES AND FISCHETTI
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TABLE III
Characterization ofAnti-M6 Synthetic Peptide Sera
" Sequence ofpeptides is the single-letter amino acid code.
ELISA titers are expressed as the reciprocal ofthe dilution ofserum giving an ODaos of-1.0after a 80-min incubation.
Bactericidal assay was performed as in Table I. Values are expressed as CFU and were averaged from at least four different
experiments.
1 Numbers on peptides denote their amino acid position on the M6 molecule (17). Numbers in brackets represent repeats of the
original sequence with "P" denoting a partial sequence repeat.
observed between these mAbs was the location of their epitopes, with those for
the type-specific 3118 antibody positioned within the NH2-terminal 1 /6 of the M
molecule (Jones, K. F., S. K. Hollingshead, J. R. Scott, and V. A. Fischetti,
manuscript in preparation), while those for IOB6 and 10175 were more centrally
located within this fibrous protein (Fig. 1; reference 6). Since mAb IOA11 did
not fix complement, it is not certain whether it was not opsonic because of this
or because of the location of its determinants on the molecule.
To study regions not covered by the mAbs, antisera raised against synthetic
peptides representing variousareasofthe M6 protein (Fig. 1) werealsoexamined
for their opsonizing capacities in this study. Of the six peptides tested, only the
amino terminus, S-M6(1-21), was capable of eliciting opsonic antibodies. This
was true despite the fact that the other peptides were capable of producing
antibodies with high binding titers to the native M6 protein and which had the
ability (except S-M6[308-327]) to bind to the M6 protein as presented on the
intact streptococcal cell. Anti-S-M6(308-327) antibodies did not bind to whole
cells becausethisregion ofthe Mmolecule is locatedwithin thecell wall(Pancholi,
V., and V. A. Fischetti, manuscript submitted for publication). Peptide S-M6(95-
108) may represent the fringe area of the NH2-terminal opsonogenic region of
the M6 protein, in that antibodies to this peptide showed a marginal capacity for
opsonization relative to the other peptides, but this was not significant when
compared to the amino terminus.
These studies are in agreement with previous observations that despite exten-
sive serological cross-reactions between M serotypes, protection against group A
streptococcal infection relies on type-specific opsonic antibodies produced by the
infected host (4), which react with type-specific determinants on the M protein
molecule (22). In addition, while type-specific opsonic antibodies were shown to
result in rabbits hyperimmunized with M protein or M' streptococcal cells, the
ability of these sera to opsonize heterologous M serotypes was rarely seen (23-
26). In these earlier studies, however, the location of these opsonogenic deter-
minants was unknown. More recent immunochemical analyses have indicated
that regions of the fibrillar M protein that are proximal to the cell surface
Peptide Sequence'
Anti-M6
ELISA titerf Incculum
Bactericidal)
Stationary Rotated
S-M6(1-21)1 RVFPRGTVENPDKARELLNKYC 25,600 42 2,021 57
SM6(95-108) NKGLTKKLSEAEEEC 2,560 24 >2,500 748
SM6(121-145) GTLKKTLDETVKDKIAKEQFSKETIC 8,200 22 2,186 1,720
[146-170]
[171-195]
[196-211 P]
SM6(216-285) SKQDIGALKQELAKKDEGNKC 51,200 26 >2,500 1,619
SM6(808-827) NSKLAALEKLNKELEESKKLC 25,600 26 >2,500 1,7861120 ANTIBODY BINDING LOCATION IN STREPTOCOCCAL PHAGOCYTOSIS
(COOH terminus) contain immunodeterminants more conserved among M
serotypes than those distally located (NH2 terminus) (5-7), and that the NH2-
terminal 25% of the molecule is hypervariable (2, 7, 27). Thus, as shown here,
the NH2-terminal region was likely to contain the type-specific opsonogenic
determinants of this molecule.
Only a few opsonogenic determinants on different M proteins have been
specifically identified thus far and the majority of these were type specific.
Synthetic peptides representing overlapping areas of the first 35 amino acids of
PepM5 showed that residues 14-26 could elicit type-specific opsonic antibodies
and that at least one of these epitopes was located at residues 14-20 (28).
Overlapping synthetic peptides of only the NH2-terminal 31 residues of PepM6,
from a strain other than the one used in this study, showed results similar to
those presented here in that the peptide representing the first 21 residues was
able to stimulate type-specific opsonic antibodies (13). While there is some
evidence that opsonogenic epitopes may be present in regions of the PepM24
molecule outside of the amino-terminal region, the location of these epitopes has
not yet been defined (29). A more recent study showed that a synthetic peptide
from a conserved area (residues 164-197) of the PepM5 protein was capable of
producing antibodies that were marginally effective in promoting phagocytosis
of M5, M6, and M19 streptococci (30). This finding is not compatible with our
current data and may be a matter of the stringency used to define an opsonic
antibody.
The opsonogenic epitope of mAb 3138, while not in the NH2-terminal 21
amino acids found with synthetic peptide studies (13, 28, this study), is located
at residue 41-46 (and repeated at 55-60 and 69-74) within the amino-terminal
"A" repeat region of the M6 protein. This region has been shown to be involved
in the generation of size variants of the M protein by homologous recombination
(31) as well as a region involved with antigenic diversity in the M molecule (Jones,
K. F., S. K., Hollingshead, J. R. Scott, and V. A. Fischetti, . manuscript in
preparation). Whether or not such recombination events could produce new
opsonogenic epitopes in this area will require further investigation.
Although it is clear that the NH2-terminal region of the M molecule plays an
important role in the generation of type-specific opsonic antibodies, it is uncertain
why antibodies with similar characteristics (binding titer, surface exposed epi-
topes, and complement-fixing capacity), but located more proximal to the cell
would not allow for phagocytosis. It is difficult to predict whether steric effects
imposed by the binding of the antibody in this location on the M molecule inhibit
the interaction of antibody-bound C3b with its receptor on the phagocyte.
Recent evidence suggests that fibrinogen present in human plasma reduces the
ability of cross-reactive antibodies to bind to group A streptococci (32). However,
in a more recent study, Horstmann et al. (33) have shown that M protein
specifically binds Factor H, a control protein of the alternative complement
pathway. Factor H thus prevents the deposition of C3b on the surface of the
streptococcus, preventing phagocytosis via the C3 receptors on the phagocytic
cells. Perhaps those complement-fixing antibodies bound to the central region
of the M molecule are also under the control of Factor H and, thus, are unable
to effectively bind C3, whereas, those antibodies bound to the NH2-terminalJONES AND FISCHETTI
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region bypass Factor H control . Conversely, antibodies bound within the NH2-
terminal region of theM protein allow for the deposition ofCab at this end of
the M molecule, which may not occur by the nonimmune mechanisms of the
alternative pathway (34) . Thus, C3b molecules not accessible to the regulation
of the M protein-bound Factor H would be free to interact with phagocytic
receptors . This hypothesis is currently being tested.
Summary
One of 19 mAbs against the native groupA streptococcal M6 protein proved
opsonic for type 6 organisms in a bactericidal assay. The opsonic and three
nonopsonic antibodies were selected for isotype and complement fixation studies
based on previous knowledge of their epitope site on the M6 molecule . While
mAb3B8 (IgG3), whose epitope is in the NH2-terminal hypervariable region of
the molecule (distal from the cell), and mAbs 10136 (IgG2a) and IOF5 (IgG2b),
both located in the conserved central region of the molecule, all fix complement,
IOAI1 (IgGI) did not . Only mAb 3B8 was opsonic despite the fact that mAbs
IOB6 and IOF5 both exhibited similar complement-fixing capacity, binding titer,
and surface exposure of epitopes . Analysis of antibodies raised against synthetic
peptides representing various regions of the M6 protein showed that only the
amino-terminal peptide (residues 1-21) was capable of eliciting opsonic antibod-
ies, despite the fact that peptides from other areas produced antibodies with
high-binding titers to the native M6 protein and also with the ability to bind to
intact streptococcal cells . These results not only support the observed type
specificity of opsonic antibodies, but also clearly point to the importance of the
location of antibody binding on theM molecule relative to the actual functional
capacity of the antibody with respect to the opsonization and phagocytosis of M6
streptococci . These results may underscore the recently observed role of com-
plement FactorH in the antiphagocytic activity of theM protein.
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